Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Takayasu Arteritis
NCT04882072Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ustekinumab in Takayasu arteritis (TAK), sponsored by Janssen Pharmaceutical. Started Sep 2021; status: terminated.
02
Drugs
ustekinumab
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on NCT04882072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04882072.